ISMELIN
LOE ApproachingNDAORALTABLETPriority Review
Approved
Jul 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ISMELIN is an oral small-molecule antihypertensive drug approved in 1960 by Novartis. The specific mechanism of action and approved indications are not fully documented in available data, but the drug is a legacy cardiovascular agent. It represents a historical NDA product from the early era of hypertension therapeutics.
LOE Approaching
This legacy product is approaching loss of exclusivity with minimal commercial infrastructure, suggesting a small maintenance team focused on managed decline rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ISMELIN offers very limited career growth opportunities with zero linked job openings; roles are primarily defensive, focused on compliance, supply continuity, and managed wind-down. Career development on this product is not recommended unless seeking niche expertise in legacy brand stewardship.
Product Manager (Legacy/Lifecycle)Regulatory Affairs Specialist
Worked on ISMELIN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.